3 Biotech Penny Stocks for Your August Watchlist
Biotech penny stocks are some of the hottest stocks of the past year and a half. While many investors have been focusing on popular penny stocks like AMC stock and GME stock, biotech small-caps have quietly been making big gains. There are a few good reasons for this.
For one, biotech as an industry tends to put out a great deal of news and press releases. This means that speculation is high, and therefore the potential for intraday gains is also very high. Second, there are hundreds of biotech penny stocks to watch, all progressing on individual goals and products.
While most penny stocks in other industries will show sporadic gains off of recent events, the biotech industry is always moving. For this reason, it’s important to stay up to date with any news regarding a company on your penny stocks watchlist. This is the best way to stay ahead, and avoid any unexpected price movement in your portfolio. So, with biotech in focus, here’s three that could explode next month.
3 Biotech Penny Stocks That Investors Are Watching Right Now
Enzolytics Inc. (OTC: ENZC)
Enzolytics Inc. is a biotech penny stock with multiple therapeutics in its lineup at the moment. The company’s main area of focus is on commercializing proprietary proteins to treat debilitating infectious diseases. Its therapeutics are targeted at combatting HIV, Covid, and other ailments affecting the world right now.
It’s worth noting that the company is actively anti-HIV therapeutics right now. It utilizes its monoclonal antibodies which can be developed to treat a variety of illnesses such as those mentioned above.
The latest update from Enzolytics is from mid-June. This last update could provide some context as to what the company is up to at the moment. The company announced its progress towards completing its anti-HIV ITV-1 therapeutic, and the plans to distribute it in Europe. Enzolytics has formed International Medical Partners Ltd., which is equally owned by itself and its European partners. Now, it has the licenses to distribute the therapeutic to 27 European countries covered by the European Medical Agency.
“We are excited about the progress we have made with the assistance of our partners at IMBL. Engaging Danhson Ltd., Clinical Design, and PharmaLex is an integral step toward our success in the EMA permitting process.
As this is the second time ITV-1 has gone through clinical trials and the first trials were successful, our confidence is at an all-time high regarding permitting, and with the reciprocal treaty between the EMA and FDA, we believe that the “redo” on clinical trials will be a blessing in disguise in the long run.”
The Chief Scientific Officer of Enzolytics
In the past five days alone, shares of ENZC stock have shot up by over 22% and YTD, that number jumps to well over 180%. Amid this new development, will you add ENZC stock to your watchlist?
Asensus Surgical Inc. (NYSE: ASXC)
Asensus Surgical Inc. is another biotech penny stock that is performing extremely well in the market right now. YTD, shares of ASXC stock have shot up by over 125%, with 10% or so of that coming in the last few days. In the past month, ASXC stock has been trending downwards in the market. Now, it seems that ASXC stock could be making a comeback. Because it is both a biotech stock and a penny stock, ASXC is subject to higher volatility than most others. Despite this, it continues to show just how promising its technology is.
For those who have not heard of this biotech penny stock, let’s get you up to speed on what it does. Asensus Surgical is a medical device developer. It creates products with the goal of enhancing minimally invasive surgery in the United States. The company’s products digitize the interface between the surgeon and patient.
One of its products for example, is the SurgiBot System, which is a robotically enhanced surgical device with four arms to control robotic instruments. On July 14th, Asensus Surgical announced a 510k submission to the FDA for a machine vision capabilities expansion.
“The expansion of augmented intelligence capabilities is the next driver of performance in digital surgery. This submission is an important milestone in our continued leadership with machine vision and augmented intelligence in surgery. We believe these new capabilities will support surgical planning, decision support and teaching.”
The President and CEO of ASXC, Anthony Fernando
Following ASXC’s high market performance, will you add it to your list of penny stocks to watch?
Jaguar Health Inc. (NASDAQ: JAGX)
Jaguar Health Inc. is another biotech penny stock that is increasing in value. For some context, the company develops medicines for humans and animals with diarrhea-related conditions usually stemming from HIV/AIDS. Its subsidiary Napo Pharmaceuticals Inc. also develops and commercializes plant-based gastrointestinal medicine products.
Only recently, an announcement was made that Dragon SPAC S.p.A. and Napo EU S.p.A. had closed on the financing for Dragon SPAC to receive gross proceeds of 8,830,000 euros. This financing will help to develop crofelemer, which is one of Napo’s main products.
The President and CEO of Jaguar Health, Lisa Conte said, “We are very pleased that crofelemer’s first-in-class mechanism of action may potentially benefit and change the lives of people suffering from this devastating orphan disease that leads to intestinal failure.”
In the past five days, shares of JAGX stock have shot up by over 17%, and in the past twelve months, by over 114%. With the biotech industry in focus as a result of the pandemic, Jaguar Health continues to be a top choice for investors. With this recent announcement and the uptick in mind, will you add JAGX to your watchlist?
Biotech Penny Stocks, Worth it or Not?
With so many biotech penny stocks to choose from, picking the best one can be difficult. However, the options can also make it easy to land on one that is worth buying. At the end of the day, research will always be your best friend.
In addition, putting time into learning how to trade penny stocks, will also be a major benefit to your strategy. Considering all of this, do you think that biotech penny stocks are worth it or not?